Korro Bio
Korro Bio's revenue rose 181.5% to $6 million in fiscal 2025. Its operating margin was −1,906.4%, up from −4,047.1% a year earlier. Free cash flow was −$79 million. The diluted share count rose 5.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Korro Bio does
Korro Bio is a biopharmaceutical company developing a new kind of genetic medicine based on editing RNA, the molecule that carries instructions from DNA. Its medicines are short strands of genetic material, called oligonucleotides, that use a natural editing process in cells to change a single building block of RNA. Because the change is to RNA rather than DNA, it is temporary. The company says this avoids the permanent changes that DNA editing can cause.
Its work is all in the research or preclinical stage, so it has no products to sell. It focuses on four programs it owns outright: KRRO-121 for hyperammonemia, or too much ammonia in the blood; a program for alpha-1 antitrypsin deficiency; a program on longevity and liver health; and a program for ALS. It also had up to two programs partnered with Novo Nordisk, which entered a 12-month pause in November 2025.
The company expects to deliver most of its medicines under the skin using a type of sugar attachment, known as GalNAc, that carries the drug to the liver.
Its biggest risks, as it describes them
- All its programs are in research or preclinical testing, and the risk that they fail is high.
- It has lost money since it began and expects more losses.
- It needs substantial additional funding to continue its programs.
- It relies on outside companies to run its studies and to make its medicines.
- Its Novo Nordisk partnership is on a 12-month pause.
Income statement
Korro Bio lost money in fiscal 2025: a net loss of $117 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 131 | 55 | 166 | 126 | 75 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −110.0x | −61.4x | — | — | — |
| Current ratio | 11.8x | 6.6x | 8.9x | 8.8x | 6.9x |
| Quick ratio | 11.8x | 6.6x | 8.9x | 8.8x | 6.9x |
Cash flow
Projections
Project Korro Bio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Korro Bio says to expect
- Cash runway: cash and marketable securities
Korro expects its cash, cash equivalents and marketable securities as of September 30, 2026 will fund operating expenses and capital expenditure requirements into the second half of 2028.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $2.4 million of Korro Bio shares on the open market, and 6 insiders sold $5.7 million, $5.3 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Jean Francois FormelaDirector | Sold plan | 38,490 | $14.12 | $543,479 | Form 4 |
| Sep 11, 2026 | Jean Francois FormelaDirector | Sold plan | 10,200 | $13.99 | $142,698 | Form 4 |
| Sep 11, 2026 | Oliver DolanSenior Vice President, Finance | Sold plan | 5 | $13.72 | $69 | Form 4 |
| Sep 9, 2026 | Oliver DolanSenior Vice President, Finance | Sold plan | 6 | $13.60 | $82 | Form 4 |
| Sep 8, 2026 | Oliver DolanSenior Vice President, Finance | Sold plan | 7,347 | $13.51 | $99,258 | Form 4 |
| Aug 26, 2026 | Jean Francois FormelaDirector | Sold plan | 300 | $13.96 | $4,188 | Form 4 |
| Aug 19, 2026 | Jean Francois FormelaDirector | Sold plan | 28,468 | $14.00 | $398,552 | Form 4 |
| Aug 11, 2026 | Jean Francois FormelaDirector | Sold plan | 2,143 | $13.96 | $29,916 | Form 4 |
| Aug 10, 2026 | Lynx1 Capital Management LP10% owner | Bought | 1,462 | $13.19 | $19,284 | Form 4 |
| Aug 6, 2026 | Lynx1 Capital Management LP10% owner | Bought | 5,222 | $11.40 | $59,531 | Form 4 |
| Aug 4, 2026 | Ram AiyarPresident and CEO, Director | Sold | 5,802 | $10.84 | $62,894 | Form 4 |
| Jul 6, 2026 | Jean Francois FormelaDirector | Sold plan | 9,323 | $13.96 | $130,149 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | −1,055.7% |
| Altman Z'' | 2.73 | −0.63 | −13.30 |
| Accruals ratio | −9.4% | −10.5% | −22.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put Korro Bio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Korro Bio | FY25 | 181.5% | −1,906.4% | −1,237.2% | — | — | — | |
| X4 Pharmaceuticals | FY25 | 150.0% | −1,336.7% | −1,317.2% | — | — | 3 | Compare |
| Fate Therapeutics | FY25 | −51.2% | −2,222.4% | −1,685.8% | — | — | — | Compare |
| Abeona Therapeutics | FY25 | — | −1,536.9% | −1,448.5% | — | — | — | Compare |
| Whitehawk Therapeutics | FY25 | −72.5% | −1,601.1% | −1,371.4% | — | — | — | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | — | 29 | 37 | 14 | 0 | 0 | 2 | 6 |
| Revenue growth | — | — | — | 27.8% | −62.0% | −100.0% | — | — | 181.5% |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Research and development | 12 | 12 | 19 | 37 | 61 | 42 | 57 | 64 | 66 |
| Operating income | −16 | −19 | −21 | −28 | −84 | −59 | −84 | −92 | −122 |
| Net income | −20 | −19 | −19 | −26 | −85 | −58 | −81 | −84 | −117 |
| Diluted EPS (US$) | −28.79 | −12.53 | −2.29 | −0.82 | −2.47 | −227.42 | −53.08 | −9.37 | −12.48 |
| Diluted shares (millions) | 1 | 2 | 9 | 32 | 34 | 0 | 2 | 9 | 9 |
| Cash flow | |||||||||
| Cash from operations | −15 | −17 | 34 | −45 | −76 | −54 | −67 | −60 | −79 |
| Capital expenditure | 2 | 0 | 1 | 7 | 3 | 5 | 8 | 18 | 0 |
| Free cash flow | −16 | −17 | 33 | −52 | −79 | −59 | −75 | −78 | −79 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 4 | 10 | 22 | 20 | 2 | 4 | 8 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | — | 42 | 217 | — | 131 | 55 | 166 | 126 | 75 |
| Debt incl. finance leases | — | 0 | 0 | — | — | — | — | — | — |
| Total assets | — | 44 | 223 | 265 | 185 | 74 | 222 | 226 | 114 |
| Total liabilities | — | 4 | 56 | 72 | 54 | 9 | 52 | 66 | 62 |
| Shareholders' equity | −30 | −48 | 167 | 192 | −42 | −99 | 170 | 160 | 51 |
| Margins and ratios | |||||||||
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | −71.4% | −74.5% | −597.3% | — | — | −4,047.1% | −1,906.4% |
| Net margin | — | — | −64.8% | −71.7% | −602.0% | — | — | −3,680.4% | −1,834.5% |
| Free cash flow margin | — | — | 114.5% | −140.2% | −561.4% | — | — | −3,433.6% | −1,237.2% |
| Rule of 40 (growth + FCF margin) | — | — | — | −112.5% | −623.3% | — | — | — | −1,055.7% |
| Return on capital | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −31.5% | −14.7% | −112.7% | — | −229.0% | −50.6% | −110.7% |
| Return on assets | — | — | −14.0% | −10.9% | −37.6% | −44.8% | −55.0% | −37.3% | −69.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |